Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 300 IR Clear all
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures

NCT01721317
View directory record Official record
Conditions
Seizures
Interventions
Ezogabine/Retigabine IR, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
9
States / cities
Fresno, California • Santa Monica, California • Colorado Springs, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film

NCT01871285
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine, Placebo film, Oxycodone, Morphine sulfate, Placebo capsule
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Overland Park, Kansas • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Results available

Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.

NCT02206607
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-04937319 IR MST, PF-04937319 MR 1, PF-04937319 MR 2, PF-04937319 MR 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
High Point, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following A Low, Medium, And High-Fat Evening Meal As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers

NCT01257529
View directory record Official record
Conditions
Healthy
Interventions
Pregabalin controlled release, 330 mg, low-fat, Pregabalin controlled release, 330 mg, medium-fat, Pregabalin controlled release, 330 mg, high-fat, Pregabalin immediate release, 300 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 2 Interventional

Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients

NCT00393120
View directory record Official record
Conditions
HIV Infections
Interventions
INCB009471, Placebo comparator
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT02559206
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide, Matching Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
71
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin

NCT01686828
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease
Interventions
Acyline, Testosterone 1.62% gel, Letrozole, Placebo gel (for Testosterone 1.62% gel), Placebo pill (for Letrozole)
Drug
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder

NCT03872596
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Seroquel IR 300mg, Seroquel IR 25mg, Quetiapine Formulation A 300mg, Quetiapine Formulation B 300mg, Quetiapine Formulation 25mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

NCT03480321
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Cilostazol 100 mg, PMR 150 mg, PMR 200 mg
Drug
Lead sponsor
Genovate Biotechnology Co., Ltd.,
Industry
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

NCT03758612
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBI-223 oral suspension, TBI-223 enteric capsule, TBI-223 SR Tablet Prototype 1, TBI-223 SR Tablet Prototype 2, TBI-223 SR Tablet Prototype 3, TBI-223 IR Tablet, Placebo suspension
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR

NCT02443805
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial, House Dust Mite Allergy
Interventions
300 IR, Placebo
Biological
Lead sponsor
Stallergenes Greer
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.

NCT01332513
View directory record Official record
Conditions
Epilepsy
Interventions
Investigational Medicinal Product (MR1), Investigational Medicinal Product (MR2), Investigational Medicinal Product (MR3), Investigational Medicinal Product (MR4), Investigational Medicinal Product (MR5), Investigational Medicinal Product (IR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

NCT00955825
View directory record Official record
Conditions
Allergic Rhinitis Due to Grass Pollens
Interventions
300 IR, Placebo
Drug
Lead sponsor
Stallergenes Greer
Industry
Eligibility
18 Years to 65 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Normal, Illinois • Lexington, Kentucky • Owensboro, Kentucky + 16 more
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers

NCT02725112
View directory record Official record
Conditions
Healthy
Interventions
Pregabalin ER
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia

NCT01559272
View directory record Official record
Conditions
Schizophrenia
Interventions
Paliperidone IR (Period 1), Paliperidone palmitate F015 (Panel A: treatment group 1), Paliperidone palmitate F015 (Panel A: treatment group 2), Paliperidone palmitate F015 (Panel B: treatment group 1), Paliperidone palmitate F015 (Panel B: treatment group 2), Paliperidone palmitate F015 (Panel B: treatment group 3), Paliperidone palmitate F015 (Panel B: treatment group 4), Paliperidone palmitate F015 (Panel B: treatment group 5), Paliperidone palmitate F016, Paliperidone palmitate F015 (Panel D: treatment group 1), Paliperidone palmitate F015 (Panel D: treatment group 2), Paliperidone palmitate F015 (Panel D: treatment group 3), Paliperidone palmitate F015 (Panel D: treatment group 4)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
10
States / cities
Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers

NCT01508182
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin tablets, Metformin IR tablets, Canagliflozin/metformin IR FDC tablets
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

NCT01106677
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin immediate release
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
45
States / cities
Little Rock, Arkansas • Fountain Valley, California • National City, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 21, 2026, 5:49 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

NCT06500793
View directory record Official record
Conditions
Pharmacokinetics, Healthy Volunteer
Interventions
PF614 capsule, Nafamostat Mesylate
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of 300 mg Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars

NCT03785756
View directory record Official record
Conditions
Pain
Interventions
Ibuprofen 300 mg Oral Tablet, Ibuprofen 200 mg Oral Tablet, Placebo of PR tablet, Placebo of IR tablet
Drug
Lead sponsor
Reckitt Benckiser Healthcare (UK) Limited
Industry
Eligibility
18 Years to 50 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers

NCT01518712
View directory record Official record
Conditions
Healthy
Interventions
A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 29, 2012 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications

NCT04885530
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
10,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
110
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

NCT01463228
View directory record Official record
Conditions
Healthy
Interventions
A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced Oct 21, 2026, 5:49 PM EDT
Terminated Phase 4 Interventional

Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome

NCT02117076
View directory record Official record
Conditions
Restless Leg Syndrome
Interventions
Gabapentin immediate release, Gabapentin enacarbil extended release
Drug
Lead sponsor
Theresa Zesiewicz, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Results available

A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.

NCT00905489
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine Immediate Release (IR), Nevirapine Extended Release (XR)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
3 Years to 17 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Oct 21, 2026, 5:49 PM EDT